- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT04805021
Emofilia A acquisita e autoimmunità. Studio delle popolazioni di linfociti e cellule soppressori di derivazione mieloide (IMMUNHEMAC)
Acquired hemophilia A is a rare condition of hemostasis secondary to the development of antibodies against factor VIII. This is a potentially serious pathology that can be life-threatening due to the major risk of bleeding caused by the sometimes drastic decrease in the level of circulating factor VIII.
This pathology occurs overwhelmingly in elderly subjects or, more rarely, in young women, during the postpartum period. It appears idiopathic in 50% of cases and associated, for the other cases, with underlying pathologies such as autoimmune pathologies (rheumatoid arthritis and bullous pemphigoid in particular) and neoplasias, or with a particular circumstance represented by the post -partum.
The association between this autoimmune pathology and its association with pathologies of the same type or with circumstances involving the immune system, suggests that common mechanisms could favor its emergence.
This study therefore proposes to study lymphocyte populations and subpopulations as well as Myeloid-Derived Suppressor Cells and the cytokine profile, which are abnormal in a large part of autoimmune pathologies.
Panoramica dello studio
Tipo di studio
Iscrizione (Effettivo)
Contatti e Sedi
Luoghi di studio
-
-
-
Nantes, Francia
- CHU de Nantes
-
Saint-Nazaire, Francia
- CH de Saint Nazaire
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Metodo di campionamento
Popolazione di studio
Patients with acquired hemophilia A will be recruited prospectively when diagnosed with acquired hemophilia A and will be followed in the study until recovery.
Patients with constitutional hemophilia A will be recruited prospectively. They should be over 50 years old and have severe or moderate hemophilia A, and not be taking any treatment that could interfere with the immune system or inflammatory markers.
Population of control subjects without coagulation abnormalities, over 60 years of age and not taking any treatment likely to interfere with the immune system or inflammatory markers.
Patient population with inflammatory pathology will include subjects with an inflammatory pathology likely, according to the literature, to be associated with acquired hemophilia A and, in particular patients with rheumatoid arthritis, if possible at diagnosis and not taking any treatment likely to interfere with the disease. immune system or inflammatory markers.
Descrizione
Inclusion Criteria:
-
Patient population with acquired hemophilia A:
Adult patients with a diagnosis of acquired hemophilia A and with a social security system. Obtaining oral non-opposition from the patient to participate in the study following the submission of an information note relating to the project.
Obtaining signed and written informed consent for biocollection consent.
-
Population of Patients with constitutional hemophilia A:
Adult patients over 50 years of age with severe or moderate constitutional hemophilia A, with no history of autoimmune disease, and with a social security system.
Obtaining oral non-opposition from the patient to participate in the study following the submission of an information note relating to the project.
Obtaining signed and written informed consent for biocollection consent.
-
Population of control subjects:
Adult patients, over the age of 60, without a coagulation abnormality, with no history of autoimmune disease, and with a social security system.
Obtaining oral non-opposition from the patient to participate in the study following the submission of an information note relating to the project.
Obtaining signed and written informed consent for biocollection consent.
-
Patient population with inflammatory pathology:
Adult patients over the age of 50 with an inflammatory pathology likely to be associated with acquired hemophilia A, and with a social security system.
Obtaining oral non-opposition from the patient to participate in the study following the submission of an information note relating to the project.
Obtaining signed and written informed consent for biocollection consent.
Exclusion Criteria:
For the 4 groups:
- Minor patient, under guardianship or curatorship.
- Pregnant and lactating women.
- Blood transfusion less than 7 days old.
- Treatment with corticosteroids in the 7 days preceding inclusion or any other immunomodulatory or immunosuppressive treatment in the 4 weeks preceding inclusion.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Modelli osservazionali: CASE_CONTROL
- Prospettive temporali: PROSPECTIVE
Coorti e interventi
Gruppo / Coorte |
Intervento / Trattamento |
|---|---|
|
Pazienti nel gruppo di emofilia acquisita A.
|
no intervention |
|
pazienti nel gruppo dell'emofilia A costituzionale.
|
no intervention |
|
pazienti nel gruppo dei soggetti di controllo.
|
no intervention |
|
pazienti nel gruppo di pazienti con patologia infiammatoria.
|
no intervention |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Evaluate the evolution of lymphocyte populations and subpopulations, MDSCs and inflammatory cytokines in patients with hemophilia A acquired at diagnosis and during follow-up
Lasso di tempo: 2 years
|
Comparisons between diagnosis and during follow-up |
2 years
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
To test the link between the severity of the disease at diagnosis and the cellular and cytokine parameters.
Lasso di tempo: 2 years
|
Factor VIII level and inhibitor titration at diagnosis |
2 years
|
|
Comparisons of baseline lymphocyte and cytokine data between patients with a favorable versus unfavorable final diagnosis.
Lasso di tempo: 2 years
|
Cell populations and cytokine profile and half-life of the inhibitor under treatment, time before normalization of the Factor VIII / Willebrand factor ratio, total duration of treatment with corticosteroids, recurrence and mortality tested to define a favorable course of the disease or unfavorable. |
2 years
|
|
Comparison of lymphocyte populations and subpopulations, MDSCs and inflammatory cytokines between different groups.
Lasso di tempo: 2 years
|
Cell populations and cytokine profile of the different groups at diagnosis and at the end of follow-up. |
2 years
|
Collaboratori e investigatori
Sponsor
Investigatori
- Investigatore principale: Marc Fouassier, Nantes University Hospital
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
- Malattie genetiche, congenite
- Malattie ematologiche
- Disturbi della coagulazione del sangue
- Disturbi emorragici
- Disturbi della coagulazione del sangue, ereditari
- Disturbi delle proteine della coagulazione
- Malattie e anomalie congenite, ereditarie e neonatali
- Malattie emiche e linfatiche
- Emofilia A
Altri numeri di identificazione dello studio
- RC20_0253
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .